MedPath

Corticotropin

Generic Name
Corticotropin
Brand Names
Acthar, Cortrophin
Drug Type
Biotech
CAS Number
12427-33-7
Unique Ingredient Identifier
K0U68Q2TXA
Background

Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication

For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions
Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis
Clinical Trials
Related News

Crinecerfont Shows Promise in Pediatric Congenital Adrenal Hyperplasia Across All Patient Subgroups

• Phase 3 CAHtalyst pediatric study demonstrates that crinecerfont (CRENESSITY) effectively reduces glucocorticoid dosing while maintaining or improving androstenedione levels in children with classic congenital adrenal hyperplasia. • The CRF1 receptor antagonist showed consistent benefits across all patient subgroups regardless of demographic characteristics, baseline androstenedione levels, or baseline glucocorticoid dose. • By enabling reduced reliance on high-dose glucocorticoids, crinecerfont addresses both the hormonal imbalances of CAH and the complications associated with traditional steroid treatments.

Mineralys Therapeutics' Lorundrostat Advances to Phase 2 for Obstructive Sleep Apnea and Hypertension

• Mineralys Therapeutics' lorundrostat receives FDA clearance for a Phase 2 trial targeting obstructive sleep apnea (OSA) in hypertensive patients. • The trial aims to assess lorundrostat's efficacy in reducing upper airway obstruction and nocturnal hypertension in moderate-to-severe OSA. • The Phase 2 study is set to commence in Q1 2025, evaluating 50mg of lorundrostat daily in approximately 40 participants. • Mineralys' Explore-CKD Phase 2 trial, evaluating lorundrostat for hypertension in CKD patients with albuminuria, has completed enrollment.

Breakthrough Year in Multiple Sclerosis Research: Key Advances and Treatment Milestones in 2024

2024 marked significant progress in multiple sclerosis treatment and research, highlighted by the revision of McDonald diagnostic criteria and breakthrough clinical trials. Notable developments included positive results for tolebrutinib in non-relapsing SPMS and promising outcomes for ublituximab in treatment transitions, representing major steps forward in MS care.

FDA Approves Neurocrine's Crenessity (crinecerfont) for Congenital Adrenal Hyperplasia

• The FDA has approved Crenessity (crinecerfont) as an adjunctive treatment for congenital adrenal hyperplasia (CAH) in adults and children, marking a significant advancement. • Crenessity is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production. • Clinical trials demonstrated that Crenessity enables lower glucocorticoid doses while maintaining or improving androgen control in CAH patients. • Neurocrine Biosciences expects Crenessity to be commercially available soon, offering a new treatment option for individuals with classic CAH.

FDA Grants Priority Review to Crinecerfont for Congenital Adrenal Hyperplasia

• The FDA has accepted two New Drug Applications for Neurocrine Biosciences' crinecerfont, granting Priority Review for treating classic congenital adrenal hyperplasia (CAH). • Crinecerfont, a selective CRF1 receptor antagonist, aims to manage ACTH and androgen levels without glucocorticoids, potentially revolutionizing CAH treatment. • If approved, crinecerfont would be the first new CAH treatment in 70 years, offering a novel mechanism to address this rare endocrine disorder. • The CAH market is expected to grow significantly, driven by emerging therapies like crinecerfont, with a projected CAGR of ~40% to reach USD 20 billion by 2034.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy